EA200701053A1 - Продукт конъюгации - Google Patents

Продукт конъюгации

Info

Publication number
EA200701053A1
EA200701053A1 EA200701053A EA200701053A EA200701053A1 EA 200701053 A1 EA200701053 A1 EA 200701053A1 EA 200701053 A EA200701053 A EA 200701053A EA 200701053 A EA200701053 A EA 200701053A EA 200701053 A1 EA200701053 A1 EA 200701053A1
Authority
EA
Eurasian Patent Office
Prior art keywords
product
conventions
peptide
selectively inhibiting
ngr motif
Prior art date
Application number
EA200701053A
Other languages
English (en)
Other versions
EA013967B1 (ru
Inventor
Анжело Корти
Флавио Курнис
Original Assignee
Мольмед Спа
Фондационе Чентро Сан Рафаэле Дель Монтэ Табор
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мольмед Спа, Фондационе Чентро Сан Рафаэле Дель Монтэ Табор filed Critical Мольмед Спа
Publication of EA200701053A1 publication Critical patent/EA200701053A1/ru
Publication of EA013967B1 publication Critical patent/EA013967B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Пептид, селективно ингибирующий интегрин αβи содержащий продукт дезамидирования пептида, содержащего мотив NGR.
EA200701053A 2004-12-23 2005-12-21 Продукт конъюгации EA013967B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63815804P 2004-12-23 2004-12-23
PCT/IB2005/004058 WO2006067633A2 (en) 2004-12-23 2005-12-21 Conjugation product

Publications (2)

Publication Number Publication Date
EA200701053A1 true EA200701053A1 (ru) 2008-06-30
EA013967B1 EA013967B1 (ru) 2010-08-30

Family

ID=36602131

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701053A EA013967B1 (ru) 2004-12-23 2005-12-21 Продукт конъюгации

Country Status (13)

Country Link
US (2) US7795386B2 (ru)
EP (2) EP1831254B1 (ru)
JP (1) JP2008525424A (ru)
KR (1) KR20070102684A (ru)
CN (1) CN101124243A (ru)
AU (1) AU2005317684B2 (ru)
CA (1) CA2593964A1 (ru)
EA (1) EA013967B1 (ru)
ES (1) ES2388068T3 (ru)
HK (1) HK1106781A1 (ru)
IL (2) IL183710A (ru)
NO (1) NO20073244L (ru)
WO (1) WO2006067633A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124726A2 (en) * 2005-05-12 2006-11-23 The General Hospital Corporation Novel biotinylated compositions
GB0624308D0 (en) * 2006-12-05 2007-01-17 Molmed Spa Combination product
GB0708864D0 (en) * 2007-05-08 2007-06-13 Molmed Spa Cytokine Conjugate
SI2209805T1 (sl) 2007-10-30 2017-11-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
KR101629913B1 (ko) * 2008-05-13 2016-06-13 몰메드 에스피에이 중피종 치료용 접합체
US8636978B2 (en) 2008-06-23 2014-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclized NGR peptide compounds, compositions, and methods of their use
EP2365815B1 (en) 2008-11-14 2019-09-18 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8946379B2 (en) 2009-09-24 2015-02-03 The Regents Of The University Of California Bladder cancer specific ligand peptides
ES2872964T3 (es) * 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
GB201204868D0 (en) * 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US10024860B2 (en) 2012-03-28 2018-07-17 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
WO2013148259A1 (en) * 2012-03-28 2013-10-03 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
US9234007B2 (en) 2012-07-02 2016-01-12 University Of South Florida RGD mimetic γ-AApeptides and methods of use
JP6431480B2 (ja) 2012-08-31 2018-11-28 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の治療および診断のためのビオチン複合体
US9695232B2 (en) 2012-10-03 2017-07-04 Philogen S.P.A. Anti-ED-A immunoconjugates for inflammatory bowel disease
WO2015031084A1 (en) 2013-08-28 2015-03-05 Jianfeng Cai Methods of synthesizing y-aapeptides, y-aapeptide building blocks, y-aapeptide libraries, and y-aapeptide inhibitors of ab40 aggregates
FR3010527A1 (fr) * 2013-09-11 2015-03-13 Univ Claude Bernard Lyon Procede de caracterisation de particules
CN103483422B (zh) * 2013-09-22 2015-06-17 中国人民解放军第四军医大学 一种ngr多肽放射性药物及其制备方法与应用
US20170168074A1 (en) 2013-11-25 2017-06-15 Ontochem Gmbh Method for diagnosing G-protein coupled receptor-related diseases
KR20180030180A (ko) 2015-07-16 2018-03-21 필로겐 에스.피.에이. Il22 면역컨쥬게이트
CN108699164B (zh) * 2016-03-02 2022-06-07 法玛科技顾问股份有限公司 双重标靶药物载体
WO2020109625A1 (en) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
IL68100A0 (en) 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
WO1984002129A1 (en) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5196511A (en) * 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
DE773441T1 (de) 1995-09-11 1999-03-04 La Jolla Cancer Research Foundation, La Jolla, Calif. Moleküle, die sich in ausgewählten Organen oder Geweben invivo Einfinden und Verfahren zu ihrer Identifizierung
US6068829A (en) * 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
JP2001501600A (ja) * 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
WO2000067771A1 (en) 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US7544477B2 (en) * 2000-01-13 2009-06-09 Kalobios, Inc. Circularly permutated, interaction-activated proteins
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US6825167B1 (en) * 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
AU2002232568A1 (en) 2000-12-11 2002-06-24 Regents Of The University Of Michigan Compositions and methods for in situ and in vivo imaging of cells and tissues
ATE550345T1 (de) 2001-01-10 2012-04-15 Us Health Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
EP1381384B1 (en) 2001-04-24 2011-05-25 Merck Patent GmbH COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate

Also Published As

Publication number Publication date
EP2364995A1 (en) 2011-09-14
EA013967B1 (ru) 2010-08-30
JP2008525424A (ja) 2008-07-17
EP1831254A2 (en) 2007-09-12
CA2593964A1 (en) 2006-06-29
HK1106781A1 (en) 2008-03-20
US7795386B2 (en) 2010-09-14
IL183710A (en) 2012-01-31
WO2006067633A2 (en) 2006-06-29
CN101124243A (zh) 2008-02-13
ES2388068T3 (es) 2012-10-08
IL202570A0 (en) 2011-08-01
EP1831254B1 (en) 2012-06-06
US20090068106A1 (en) 2009-03-12
NO20073244L (no) 2007-09-20
AU2005317684A1 (en) 2006-06-29
KR20070102684A (ko) 2007-10-19
WO2006067633A3 (en) 2007-04-05
US20110076234A1 (en) 2011-03-31
IL183710A0 (en) 2008-04-13
AU2005317684B2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
EA200701053A1 (ru) Продукт конъюгации
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NL1029105A1 (nl) Tetraazabenz[e]azuleenderivaten en analogen daarvan.
ZA200710385B (en) Heterocyclic aspartyl protease inhibitors, preparation and use thereof
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
GB2436266A (en) Modified human growth hormone
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
ATE536109T1 (de) Kleidungsstück mit verbesserter kniestütze
GB2430677A8 (en) Novel antigenbinding polypeptides and their uses
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
SG165353A1 (en) Improved human interferon molecules and their uses
EP1782370A4 (en) PRODUCTION AND / OR DELIVERY OF LOCAL ADVERTISING, SUCH AS, FOR EXAMPLE, ADVERTISING FOR CALL FUNCTIONALITY FACILITIES
CA114146S (en) Correction and glue tape dispenser
CA114713S (en) Container for fuel paste
HK1130054A1 (en) Novel, acyclic substituted furopyrimidine derivatives and use thereof
MX296535B (es) Enzima laccasa novedosa y uso de la misma.
CA119778S (en) Package
CA118651S (en) Open-mouth container
EP1802332A4 (en) MODIFIED HIV-1 CREAM PROTEINS
GB0521958D0 (en) vWFA, collagen and kunitz domain containing protein
WO2006069182A3 (en) THIENOISOQUINOLINE-PHENYLSULFONAMIDES AND THEIR USE AS ER-NFkB INHIBITORS
CA111951S (en) Planter
CA111977S (en) Planter
CA117637S (en) Planter

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU